These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35768912)

  • 21. Bedaquiline: Current status and future perspectives.
    Khoshnood S; Goudarzi M; Taki E; Darbandi A; Kouhsari E; Heidary M; Motahar M; Moradi M; Bazyar H
    J Glob Antimicrob Resist; 2021 Jun; 25():48-59. PubMed ID: 33684606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
    Maartens G; Brill MJE; Pandie M; Svensson EM
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
    Han X; Chen X; Sha W; Zhang X; Qiu L; Wang J; Wu G; Yao L; Lv Y; Zhang X; Zhou J; Tang S; Chu N
    Int J Tuberc Lung Dis; 2020 Aug; 24(8):789-794. PubMed ID: 32912383
    [No Abstract]   [Full Text] [Related]  

  • 24. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
    Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Introduction of bedaquiline for the treatment of drug-resistant TB in the Philippines.
    Santiago MR; Garfin AMC; Balanag VM
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1063-1066. PubMed ID: 33126940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.
    Ndjeka N; Conradie F; Schnippel K; Hughes J; Bantubani N; Ferreira H; Maartens G; Mametja D; Meintjes G; Padanilam X; Variava E; Pym A; Pillay Y
    Int J Tuberc Lung Dis; 2015 Aug; 19(8):979-85. PubMed ID: 26162365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data.
    Darmayani IGAAPS; Ascobat P; Instiaty I; Sugiri YJR; Sawitri N
    Acta Med Indones; 2022 Jul; 54(3):389-396. PubMed ID: 36156479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid.
    Padayatchi N; Bionghi N; Osman F; Naidu N; Ndjeka N; Master I; Brust JCM; Naidoo K; Ramjee A; O Donnell M
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1024-1031. PubMed ID: 33126934
    [No Abstract]   [Full Text] [Related]  

  • 29. Overcoming barriers to the access and uptake of newer drugs for multidrug-resistant TB.
    Zabsonre I; Thi SS; Cox V
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1054-1057. PubMed ID: 33126938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bedaquiline for multidrug-resistant TB in paediatric patients.
    Moodliar R; Aksenova V; Frias MVG; van de Logt J; Rossenu S; Birmingham E; Zhuo S; Mao G; Lounis N; Kambili C; Bakare N
    Int J Tuberc Lung Dis; 2021 Sep; 25(9):716-724. PubMed ID: 34802493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation.
    Kim JH; Kwon OJ; Kim YS; Park MS; Hwang S; Shim TS
    Respir Investig; 2020 Jan; 58(1):45-51. PubMed ID: 31635903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.
    Salifu EY; Agoni C; Olotu FA; Soliman MES
    Comput Biol Chem; 2020 Apr; 85():107204. PubMed ID: 31981966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.
    Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y
    Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
    Sarin R; Vohra V; Singla N; Singla R; Puri MM; Munjal SK; Khalid UK; Myneedu VP; Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):184-188. PubMed ID: 30878066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study.
    Byun JH; Park JA; Kang HR; Shin JY; Lee EK
    Clin Drug Investig; 2016 Nov; 36(11):957-968. PubMed ID: 27465204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selected questions and controversies about bedaquiline: a view from the field.
    Dheda K; Esmail A; Limberis J; Maartens G
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):24-32. PubMed ID: 28240569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
    Das M; Dalal A; Laxmeshwar C; Ravi S; Mamnoon F; Meneguim AC; Paryani R; Mathur T; Singh P; Mansoor H; Kalon S; Hossain FN; Lachenal N; Coutisson S; Ferlazzo G; Isaakidis P
    Clin Infect Dis; 2021 Nov; 73(9):e3496-e3504. PubMed ID: 33079176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
    Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.